PANACEA LIFE SCIENCE HLD (PLSH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 14, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2024, filed May 6, 2024. Each column of the statement tables below links to the filing it was taken from.
PANACEA LIFE SCIENCE HLD (PLSH) reported $2.4M in revenue for fiscal year 2023, up 3.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Improving gross margins have not overcome persistent operating losses, weak short-term coverage, and a balance sheet funded heavily by obligations.
From FY2022 to FY2023, gross margin rose from17.2% to47.0% while revenue barely changed, but operating margin remained deeply negative at-245.8% and-232.6% . That combination indicates better economics after direct costs, yet insufficient scale or cost absorption to support the broader operating structure.
The FY2023 net loss was
Liabilities of
Financial Health Signals
PANACEA LIFE SCIENCE HLD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
PANACEA LIFE SCIENCE HLD scores -4.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($3.9M) relative to total liabilities ($26.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
PANACEA LIFE SCIENCE HLD passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
PANACEA LIFE SCIENCE HLD reported a net loss of $8.0M while operations used $1.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
PANACEA LIFE SCIENCE HLD reported an operating loss of $5.5M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
PANACEA LIFE SCIENCE HLD generated $1.1M in revenue in Q1 2024. This represents an increase of 55.9% from the same quarter a year earlier. Against the prior quarter it is up 10.0%.
PANACEA LIFE SCIENCE HLD's EBITDA was -$674K in Q1 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is up 49.1%.
PANACEA LIFE SCIENCE HLD reported -$1.4M in net income in Q1 2024. This represents an increase of 19.3% from the same quarter a year earlier. Against the prior quarter it is up 34.5%.
PANACEA LIFE SCIENCE HLD earned -$0.09 per diluted share (EPS) in Q1 2024. This represents an increase of 25.0% from the same quarter a year earlier. Against the prior quarter it is up 30.8%.
Cash & Balance Sheet
PANACEA LIFE SCIENCE HLD recorded an outflow of $362K in free cash flow in Q1 2024, representing a cash shortfall after capex. This represents a decrease of 10.0% from the same quarter a year earlier.
PANACEA LIFE SCIENCE HLD held $108K in cash as of Q1 2024; long-term debt is not reported for that period.
Not reported for Q1 2024.
Margins & Returns
PANACEA LIFE SCIENCE HLD's gross margin was 63.1% in Q1 2024, indicating the percentage of revenue retained after direct costs. This is up 29.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 6.1 percentage points.
Not shown for Q1 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q1 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q1 2024.
Capital Allocation
PANACEA LIFE SCIENCE HLD invested $5K in capex in Q1 2024, funding long-term assets and infrastructure. This represents a decrease of 67.1% from the same quarter a year earlier.
Not reported for Q1 2024.
Not reported for Q1 2024.
PLSH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M+55.9% | $960K-3.7% | $348K-5.0% | $399K-15.0% | $677K+45.2% | $998K+54.5% | $366K-37.7% | $469K+49.8% |
| Cost of Revenue | $390K-13.6% | $414K+93.3% | $201K-36.9% | $196K-40.8% | $452K+23.4% | $214K-66.3% | $319K+4.6% | $332K+33.3% |
| Gross Profit | $666K+195.3% | $547K+393.7% | $147K+209.8% | $203K+47.0% | $226K+124.7% | $111K+964.1% | $47K-83.3% | $138K+112.8% |
| SG&A Expenses | $249K-3.3% | $777K+366.3% | $277K+5.8% | $145K-29.1% | $257K-44.1% | $167K-72.5% | $262K-10.0% | $205K-38.9% |
| Operating Income | -$1.1M+18.0% | -$1.8M-28.5% | -$1.4M-1.8% | -$1.1M+13.4% | -$1.3M+21.7% | -$1.4M+36.0% | -$1.4M-10.4% | -$1.2M+13.9% |
| EBITDA | -$674K+22.3% | -$1.3M-42.3% | -$990K-4.0% | -$651K+20.1% | -$867K+29.1% | -$931K+46.4% | -$952K-11.9% | -$815K+15.5% |
| Interest Expense | $430K+13.0% | $412K+8.8% | $397K-33.7% | $367K-35.6% | $380K-24.2% | $379K+17.1% | $598K+242.2% | $570K+100.4% |
| Net Income | -$1.4M+19.3% | -$2.2M-29.6% | -$2.2M+20.1% | -$1.9M+5.0% | -$1.8M+35.6% | -$1.7M+18.5% | -$2.7M+12.8% | -$2.0M-7308.8% |
| EPS (Basic) | -$0.09+25.0% | -$0.13-8.3% | -$0.13+27.8% | -$0.11+15.4% | -$0.12+25.0% | -$0.120.0% | -$0.180.0% | -$0.13 |
| EPS (Diluted) | -$0.09+25.0% | -$0.13-8.3% | -$0.13+27.8% | -$0.11+15.4% | -$0.12+36.8% | -$0.12 | -$0.18-28.6% | -$0.13 |
| Diluted Shares (Avg) | 16M+10.2% | N/A | 17M+11.8% | 18M+17.9% | 15M+1.4% | N/A | 15M-30.5% | 15M |
Not reported in any period shown, so not listed: R&D Expenses, Income Tax.
PLSH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.4M-6.2% | $18.0M-7.7% | $18.7M-6.3% | $17.9M-18.7% | $18.6M-17.2% | $19.5M-18.1% | $20.0M-17.3% | $22.0M-18.0% |
| Current Assets | $4.6M-21.9% | $4.7M-27.0% | $5.9M-9.4% | $5.7M-29.2% | $5.9M-26.8% | $6.4M-29.9% | $6.5M-29.5% | $8.1M-28.2% |
| Cash & Equivalents | $108K+47.0% | $101K+1351.9% | $1K-95.9% | $8K-77.6% | $73K+30.8% | $7K-64.8% | $37K+153.7% | $37K-72.1% |
| Short-Term Investments | $10K-99.0% | $15K-98.7% | $78K-93.0% | $460K-82.0% | $925K-67.5% | $1.1M-70.8% | $1.1M-69.3% | $2.6M-57.3% |
| Inventory | $4.1M-0.8% | $4.0M-9.8% | $4.7M+6.3% | $4.4M-2.7% | $4.1M-5.3% | $4.4M+4.3% | $4.4M+1.6% | $4.5M+4.8% |
| Accounts Receivable | $271K-1.4% | $264K+28.1% | $309K+39.2% | $272K+23.9% | $275K+69.0% | $206K-15.7% | $222K-56.9% | $220K-24.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $3.0M+37.7% | $3.0M+37.7% | $3.0M+37.7% | $2.2M0.0% | $2.2M0.0% | $2.2M0.0% | $2.2M0.0% | $2.2M0.0% |
| Total Liabilities | $27.0M+20.9% | $26.3M+21.5% | $24.8M+21.5% | $23.4M+18.8% | $22.4M+22.6% | $21.6M+29.7% | $20.4M+29.5% | $19.7M+28.9% |
| Current Liabilities | $20.4M+28.3% | $19.4M+29.0% | $18.5M+34.2% | $17.0M+30.5% | $15.9M+37.5% | $15.1M+49.7% | $13.8M+48.6% | $13.1M+49.6% |
| Non-Current Liabilities | $6.6M+2.7% | $6.8M+4.1% | $6.3M-5.0% | $6.4M-4.1% | $6.5M-3.1% | $6.6M-0.8% | $6.6M+2.0% | $6.6M+1.3% |
| Total Equity | -$9.6M-153.2% | -$8.3M-286.6% | -$6.1M-1282.7% | -$5.6M-347.0% | -$3.8M-190.9% | -$2.1M-130.2% | -$440K-105.2% | $2.3M-80.4% |
| Retained Earnings | -$35.4M-27.7% | -$33.9M-30.9% | -$31.7M-31.0% | -$29.6M-37.4% | -$27.7M-41.7% | -$25.9M-54.5% | -$24.2M-64.9% | -$21.5M-85.7% |
Not reported in any period shown, so not listed: Long-Term Debt.
PLSH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$357K-13.8% | $2K+100.3% | -$729K-2.5% | -$483K+33.7% | -$314K+28.0% | -$523K+57.5% | -$711K+5.5% | -$729K+36.3% |
| Depreciation & Amortization | $383K-9.2% | $444K-0.3% | $424K-3.0% | $423K-0.6% | $423K-0.4% | $445K+8.3% | $437K+7.2% | $425K-10.6% |
| Capital Expenditures | $5K-67.1% | N/A | N/A | $9K+18.7% | $15K+56.5% | $99K+945.8% | $127K+822.9% | $8K-92.1% |
| Free Cash Flow | -$362K-10.0% | N/A | N/A | -$493K+33.2% | -$329K+26.2% | -$622K+49.8% | -$838K-9.4% | -$737K+40.7% |
| Investing Cash Flow | -$5K+67.1% | -$18K+81.9% | -$23K+82.1% | -$9K-124.0% | -$15K-56.5% | -$99K-1145.8% | -$127K-152.2% | $39K-89.1% |
| Financing Cash Flow | $369K-6.7% | $116K-80.4% | $745K-11.2% | $428K-36.3% | $395K-18.0% | $592K-51.7% | $839K+113.8% | $671K-18.4% |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
PLSH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2410-Q | Q4'2310-Q | Q3'2310-K | Q2'2310-Q | Q1'2310-Q | Q4'2210-K | Q3'2210-K | Q2'2210-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.1%+29.8pp | 56.9%+45.8pp | 42.1%+29.2pp | 50.8%+21.4pp | 33.3%+11.8pp | 11.1%+9.5pp | 12.9%-35.2pp | 29.4%+8.7pp |
| Operating Margin | -100.1% | -184.1% | -406.5% | -269.1% | -190.4% | -137.9% | -379.2% | -264.1% |
| Net Margin | -136.9% | -230.0% | -618.4% | -467.1% | -264.4% | -170.8% | -735.6% | -417.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -87.0%-87.3pp |
| Return on Assets | -8.3%+1.3pp | -12.3%-3.5pp | -11.5%+2.0pp | -10.4%-1.5pp | -9.7%+2.8pp | -8.8%0.0pp | -13.5%-0.7pp | -8.9%-9.0pp |
| Current Ratio | 0.23-0.1x | 0.24-0.2x | 0.32-0.2x | 0.34-0.3x | 0.37-0.3x | 0.42-0.5x | 0.47-0.5x | 0.62-0.7x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 8.75+7.4x |
| Asset Turnover | 0.060.0x | 0.050.0x | 0.020.0x | 0.020.0x | 0.040.0x | 0.050.0x | 0.020.0x | 0.020.0x |
| FCF Margin | -34.3%+14.3pp | N/A | N/A | -123.4% | -48.6%+47.0pp | -62.3% | -228.9% | -157.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$8.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.24), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PANACEA LIFE SCIENCE HLD PLSH | FY2023 | $2.4M | -$8.0M | N/A | $3.9M | — |
| CAN B CORP CANB | FY2023 | $2.2M | -$9.7M | N/A | $1.4M | — |
Where PANACEA LIFE SCIENCE HLD Ranks
Frequently Asked Questions
What is PANACEA LIFE SCIENCE HLD's annual revenue?
PANACEA LIFE SCIENCE HLD (PLSH) reported $2.4M in total revenue for fiscal year 2023. This represents a 3.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is PANACEA LIFE SCIENCE HLD's revenue growing?
PANACEA LIFE SCIENCE HLD (PLSH) revenue grew by 3.7% year-over-year, from $2.3M to $2.4M in fiscal year 2023.
Is PANACEA LIFE SCIENCE HLD profitable?
No, PANACEA LIFE SCIENCE HLD (PLSH) reported a net income of -$8.0M in fiscal year 2023.
What is PANACEA LIFE SCIENCE HLD's EBITDA?
PANACEA LIFE SCIENCE HLD (PLSH) had EBITDA of -$3.8M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.
What is PANACEA LIFE SCIENCE HLD's gross margin?
PANACEA LIFE SCIENCE HLD (PLSH) had a gross margin of 47.0% in fiscal year 2023, indicating the percentage of revenue retained after direct costs of goods sold.
What is PANACEA LIFE SCIENCE HLD's free cash flow?
PANACEA LIFE SCIENCE HLD (PLSH) recorded an outflow of $1.6M in free cash flow during fiscal year 2023. This represents a 39.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is PANACEA LIFE SCIENCE HLD's operating cash flow?
PANACEA LIFE SCIENCE HLD (PLSH) recorded an outflow of $1.5M in operating cash flow during fiscal year 2023, representing cash used by core business activities.
What are PANACEA LIFE SCIENCE HLD's total assets?
PANACEA LIFE SCIENCE HLD (PLSH) had $18.0M in total assets as of fiscal year 2023, including both current and long-term assets.
What are PANACEA LIFE SCIENCE HLD's capital expenditures?
PANACEA LIFE SCIENCE HLD (PLSH) invested $65K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.
What is PANACEA LIFE SCIENCE HLD's current ratio?
PANACEA LIFE SCIENCE HLD (PLSH) had a current ratio of 0.24 as of fiscal year 2023, which is below 1.0, which may suggest potential liquidity concerns.
What is PANACEA LIFE SCIENCE HLD's return on assets (ROA)?
PANACEA LIFE SCIENCE HLD (PLSH) had a return on assets of -44.6% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.
What is PANACEA LIFE SCIENCE HLD's P/E ratio?
PANACEA LIFE SCIENCE HLD (PLSH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2024). The market capitalization is $3.9M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PANACEA LIFE SCIENCE HLD's price-to-sales ratio?
PANACEA LIFE SCIENCE HLD (PLSH) trades at 1.4x sales, its market capitalization divided by revenue of $2.8M revenue, trailing 12 months to March 31, 2024. The market capitalization is $3.9M as of Oct 14, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does PANACEA LIFE SCIENCE HLD's liquidity compare with its operating cash outflow?
At the end of fiscal year 2023, PANACEA LIFE SCIENCE HLD (PLSH) held $116K in cash, cash equivalents and investments, and reported an operating cash outflow of $1.5M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is PANACEA LIFE SCIENCE HLD's debt-to-equity ratio negative or not reported?
PANACEA LIFE SCIENCE HLD (PLSH) has negative shareholder equity of -$8.3M as of fiscal year 2023, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is PANACEA LIFE SCIENCE HLD's Altman Z-Score?
PANACEA LIFE SCIENCE HLD (PLSH) has an Altman Z-Score of -4.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is PANACEA LIFE SCIENCE HLD's Piotroski F-Score?
PANACEA LIFE SCIENCE HLD (PLSH) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PANACEA LIFE SCIENCE HLD's earnings high quality?
PANACEA LIFE SCIENCE HLD (PLSH) reported a net loss of $8.0M while operations used $1.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can PANACEA LIFE SCIENCE HLD cover its interest payments?
PANACEA LIFE SCIENCE HLD (PLSH) reported an operating loss of $5.5M against $1.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.